Isomorphic Labs raises €4.5 billion in Series C funding round
Isomorphic Labs, an AI-driven drug discovery company, has announced a €4.5 billion ($5 billion) Series C round. It was co-led by Greenoaks and Sequoia Capital.
Isomorphic Labs, a company that uses artificial intelligence to design new medicines, has announced a €4.5 billion ($5 billion) Series C financing round. The money is meant to speed up scientific progress and the company's own AI technology. The deal stands out in AI-assisted drug discovery, where other European investments in 2026 have been far smaller.
Who is investing
The round was co-led by the investment firms Greenoaks and Sequoia Capital, with Andreessen Horowitz also taking part and Alphabet continuing its significant backing. All existing investors participated: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
Founder and CEO Sir Demis Hassabis said the funding will help build foundational biology models, deepen understanding of systemic diseases and move the first therapeutic programmes towards clinical trials.
Technology and plans
Isomorphic Labs was founded in 2021. Its drug design engine, IsoDDE, combines simulation AI models that work across several therapeutic areas and drug types. It explores vast chemical spaces to design and refine molecules with suitable drug-like properties. Company President Max Jaderberg said the models deliver repeatable scientific advances every week.
The proceeds will go towards maturing IsoDDE, developing new biology models, building a partner ecosystem and creating global infrastructure for AI-led bioengineering. They will also support clinical development infrastructure as drug candidates advance towards clinical trials.
Context
EU-Startups reports that other European deals in 2026 were smaller: London-based Helical raised €8.4 million, France's Orakl Oncology €30 million and Switzerland's Adaptyv Bio €34.35 million. Together, such rounds, excluding Isomorphic Labs, come to about €148.2 million. Isomorphic Labs previously raised a €1.8 billion Series B in the first half of 2026.


